Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

22.52 -0.06 (-0.27%)
Streaming Delayed Price Updated: 9:33 AM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Acuity Brands, C3.ai And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Dyne Therapeutics
 
Via Benzinga
Chardan Initiates Coverage On These 'Intriguing Small-Cap Stories"
 
Via Benzinga
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
 
Via Benzinga
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades. 
Via Benzinga
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on... 
Via Benzinga
Dyne Therapeutics: Q3 Earnings Insights
Dyne Therapeutics (NASDAQ:DYN) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:28 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics to Present at Investor Conferences in November
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
From Dyne Therapeutics, Inc.
Via GlobeNewswire
Avidity Biosciences, Kronos Worldwide And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 180 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Dyne Therapeutics: Q2 Earnings Insights
  Dyne Therapeutics (NASDAQ:DYN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.